<DOC>
	<DOCNO>NCT00077545</DOCNO>
	<brief_summary>Drugs use chemotherapy , 3-AP cisplatin , work different way stop tumor cell divide stop grow die . 3-AP may help cisplatin kill cancer cell make sensitive drug . This phase II trial study well give 3-AP together cisplatin work treat patient recurrent metastatic adenocarcinoma esophagus gastroesophageal junction .</brief_summary>
	<brief_title>3-AP Plus Cisplatin Treating Patients With Recurrent Metastatic Adenocarcinoma Esophagus Gastroesophageal Junction</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine objective response rate patient recurrent metastatic adenocarcinoma esophagus gastroesophageal junction treat 3-AP ( Triapine ) cisplatin . SECONDARY OBJECTIVES : I . Determine toxicity regimen patient . II . Determine duration response overall survival patient treat regimen . III . Determine palliative benefit regard dysphagia patient treat regimen . OUTLINE : This multicenter study . Patients receive 3-AP ( Triapine ) IV 2 hour day 1-4 . Patients also receive cisplatin IV 60 minute day 2 3 3-AP infusion . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients follow 2 year . PROJECTED ACCRUAL : A total 19-39 patient accrue study within 20 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma esophagus gastroesophageal junction Metastatic recurrent disease Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Outside prior irradiation port No known brain metastasis Performance status ECOG 02 Performance status Karnofsky 50100 % More 6 month Absolute neutrophil count ≥ 1,500/mm^3 WBC ≥ 3,000/mm ^3 Platelet count ≥ 100,000/mm^3 AST ALT ≤ 2.5 time upper limit normal Bilirubin normal Creatine normal Creatinine clearance ≥ 50 mL/min No prior myocardial infarction No unstable angina No cardiac arrhythmia No uncontrolled congestive heart failure No pulmonary disease require supplemental oxygen Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No glucose6phosphate dehydrogenase ( G6PD ) deficiency ( patient African , Asian , Mediterranean origin ) No concurrent uncontrolled illness No active ongoing infection No active second malignancy No prior allergic reaction compound similar chemical biological composition 3AP study agent No psychiatric illness social situation would preclude study compliance At least 1 year since prior platinumderivative agent No prior chemotherapy metastatic recurrent esophageal cancer See Disease Characteristics At least 2 week since prior radiotherapy recover No concurrent anticancer therapy No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>